Prospective study of IgM to Toxoplasma gondii onTechlab Product Insert, 1997 Beckman Coulter's Access(TM) immunoassay system and comparison with Zeus ELISA and gull IFA assays

Xuhui Liu, Buffy P. Turner, Cindy E. Peyton, Barbara S. Reisner, Anthony Okorodudu, Amin A. Mohammad, Gary Hankins, Alice S. Weissfeld, John R. Petersen

Research output: Contribution to journalArticle


We compared a new assay for Toxoplasma IgM on the Access(TM) analyzer (Beckman Coulter, Inc., Chaska, MN, USA), a random access instrument based on the principle of paramagnetic particle enzyme immunoassay with an enzyme-linked immunosorbent assay (ELISA) (Zeus Scientific, Inc., Raritan, NJ, USA) and an immunofluorescent assay (IFA) (Gull Laboratories, Inc., Salt Lake City, UT, USA). Four hundred fresh, unfrozen clinical samples from pregnant women (n = 154), HIV positive patients (n = 41), and patients in whom infection with Toxoplasma gondii was suspected (n = 200) were collected and assayed over a three month period. The specificity of the Access assay was compared to the consensus results. Results that were discrepant between the ELISA and IFA were resolved using a third IFA (Zeus). Once resolved, the specificity for the Access assay, the Zeus ELISA and the Gull IFA were 99.22%, 97.91%, and 99.45%, respectively. We conclude that the Access assay specificity is comparable to consensus results, minimizing false positive results; and because it is a random access instrument, it may be preferable over batch methods. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)237-239
Number of pages3
JournalDiagnostic Microbiology and Infectious Disease
Issue number4
StatePublished - Apr 2000


ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this